pertussis whooping cough
Conditions
Interventions
None listed
Sponsors
RIVM
Eligibility
Age
2 Years to 99 Years
Inclusion criteria
Inclusion criteria: I: Patients being within a 4 weeks period after a laboratory-confirmed diagnosis of pertussis II: Household contact of I III: Subjects being recovered or recovering from a laboratory-confirmed pertussis infection which was diagnosed > 4 weeks earlier
Exclusion criteria
Exclusion criteria: A: Immunosuppressive medical treatment, like cytostatics and prednisolons that might interfere with the results of the study, within the previous 3 months. B: Any known primary or secondary immunodeficiency C: Bleeding disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main immunological study parameters: trends per age group or time interval after infection in: i) frequencies, functionality and (fine)specificity of pertussis-reactive T cells; ii) titers and functionality of pertussis specific antibody titers; and iii) frequencies, functionality and specificity of pertussis-reactive memory B cells and plasma cells | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary microbiological study parameters: strain variation of patients* pertussis isolates in relation to global trends and in relation to patients* immune responses. (per age group): estimation of pertussis incidence and underreporting in the general population, especially the elderly (by comparing the frequency of cases in source populations with national notification data); strain prevalence | — |
Countries
Netherlands
Outcome results
None listed